Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 2/20 | 0.62 |
| ▸ | USP30 | Q70CQ3 | 14/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.39 |
| ▸ | FEN1 | P39748 | 1/20 | 0.39 |
| ▸ | PARG | Q86W56 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16259615 | 0.90 | NSD2 (0.54) | NSD2USP30KDM4EMEN1NPC1 | |
| SCHEMBL19976336 | 0.83 | CDK5 (0.42) | NSD2KDM4ELMNASMN1; SMN2 | |
| SCHEMBL14328457 | 0.83 | NSD2 (0.47) | NSD2KDM4EMEN1NPC1LMNA | |
| SCHEMBL13483650 | 0.78 | NSD2 (0.68) | NSD2USP30KDM4EMEN1NPC1 | |
| SCHEMBL16849176 | 0.78 | NSD2 (0.48) | NSD2USP30KDM4EMEN1NPC1 | |
| SCHEMBL16259651 | 0.77 | NSD2 (0.43) | NSD2USP30KDM4EMEN1NPC1 | |
| SCHEMBL29968659 | 0.77 | NSD2 (1.00) | NSD2 | |
| SCHEMBL21878809 | 0.77 | NSD2 (1.00) | NSD2 | |
| SCHEMBL3577992 | 0.76 | NSD2 (0.65) | NSD2KDM4EMEN1NPC1LMNA | |
| SCHEMBL13562871 | 0.76 | CDK2 (0.56) | NSD2LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9815851-B2 | Pyrrolo carboxamides as modulators of orphan nuclear receptor RAR-related orphan receptor-gamma (RORγ, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases | PHENEX PHARMACEUTICALS AG (DE) | 2017-11-14 | — | — | US | disclosed |
| US-9815851-B2 | Pyrrolo carboxamides as modulators of orphan nuclear receptor RAR-related orphan receptor-gamma (RORγ, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases | PHENEX PHARMACEUTICALS AG (DE) | 2017-11-14 | — | — | US | disclosed |
| US-20140349987-A1 | PYRROLO CARBOXAMIDES AS MODULATORS OF ORPHAN NUCLEAR RECEPTOR RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORy, NR1F3) ACTIVITY AND FOR THE TREATMENT OF CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES | PHENEX PHARMACEUTICALS AG (DE) | 2014-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349987-A1 | PYRROLO CARBOXAMIDES AS MODULATORS OF ORPHAN NUCLEAR RECEPTOR RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORy, NR1F3) ACTIVITY AND FOR THE TREATMENT OF CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES | RORA, RORB, RORC | NSD2 2671/4885USP30 2007/4885KDM4E 2519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.